{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:35:19Z","timestamp":1791876919630,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K08501"],"award-info":[{"award-number":["22K08501"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K15323"],"award-info":[{"award-number":["23K15323"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24ek0510038"],"award-info":[{"award-number":["JP24ek0510038"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s12185-025-03957-7","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T15:44:50Z","timestamp":1740757490000},"page":"106-116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Simple and early prediction of severe CAR-T-related adverse events after Axi-cel infusion by initial high fever"],"prefix":"10.1007","volume":"122","author":[{"given":"Hiroya","family":"Wakabayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seitaro","family":"Terakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Ishigiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiya","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihomi","family":"Kuwano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6034-7909","authenticated-orcid":false,"given":"Ryo","family":"Hanajiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"issue":"1","key":"3957_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20(1):31\u201342.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3957_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356.","journal-title":"N Engl J Med"},{"issue":"10343","key":"3957_CR3","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399(10343):2294\u2013308.","journal-title":"Lancet"},{"issue":"5","key":"3957_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"issue":"7","key":"3957_CR5","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Kochenderfer JN. Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol. 2024;21(7):501\u201321.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"3957_CR6","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/ajh.26301","volume":"96","author":"JR Westin","year":"2021","unstructured":"Westin JR, Kersten MJ, Salles G, Abramson JS, Schuster SJ, Locke FL, et al. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol. 2021;96(10):1295\u2013312.","journal-title":"Am J Hematol"},{"issue":"2","key":"3957_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med. 2023;389(2):148\u201357.","journal-title":"N Engl J Med"},{"issue":"10","key":"3957_CR8","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","volume":"28","author":"E Bachy","year":"2022","unstructured":"Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022;28(10):2145\u201354.","journal-title":"Nat Med"},{"issue":"6","key":"3957_CR9","doi-asserted-by":"publisher","first-page":"584.e1","DOI":"10.1016\/j.jtct.2024.01.074","volume":"30","author":"N Gagelmann","year":"2024","unstructured":"Gagelmann N, Bishop M, Ayuk F, Bethge W, Glass B, Sureda A, et al. Axicabtagene ciloleucel versus tisagenlecleucel for relapsed or refractory large B cell lymphoma: a systematic review and meta-analysis. Transplant Cell Ther. 2024;30(6):584.e1-584.e13.","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"3957_CR10","doi-asserted-by":"publisher","first-page":"77.e1","DOI":"10.1016\/j.jtct.2023.10.017","volume":"30","author":"CA Jacobson","year":"2024","unstructured":"Jacobson CA, Munoz J, Sun F, Kanters S, Limbrick-Oldfield EH, Spooner C, et al. Real-world outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: a systematic review and meta-analysis. Transplant Cell Ther. 2024;30(1):77.e1-77.e15.","journal-title":"Transplant Cell Ther."},{"issue":"20","key":"3957_CR11","first-page":"2430","volume":"141","author":"MD Jain","year":"2023","unstructured":"Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood. 2023;141(20):2430\u201342.","journal-title":"Blood"},{"issue":"4","key":"3957_CR12","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/bjh.17527","volume":"194","author":"OO Oluwole","year":"2021","unstructured":"Oluwole OO, Bouabdallah K, Mu\u00f1oz J, De Guibert S, Vose JM, Bartlett NL, et al. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021;194(4):690\u2013700.","journal-title":"Br J Haematol"},{"issue":"3","key":"3957_CR13","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/bjh.17673","volume":"195","author":"MS Topp","year":"2021","unstructured":"Topp MS, van Meerten T, Houot R, Minnema MC, Bouabdallah K, Lugtenburg PJ, et al. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021;195(3):388\u201398.","journal-title":"Br J Haematol"},{"issue":"3","key":"3957_CR14","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41409-023-02169-z","volume":"59","author":"OO Oluwole","year":"2024","unstructured":"Oluwole OO, Forcade E, Mu\u00f1oz J, de Guibert S, Vose JM, Bartlett NL, et al. Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids. Bone Marrow Transplant. 2024;59(3):366\u201372.","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"3957_CR15","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8(8):958\u201371.","journal-title":"Cancer Discov"},{"issue":"17","key":"3957_CR16","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","volume":"5","author":"M Pennisi","year":"2021","unstructured":"Pennisi M, Sanchez-Escamilla M, Flynn JR, Shouval R, Alarcon Tomas A, Silverberg ML, et al. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Adv. 2021;5(17):3397\u2013406.","journal-title":"Blood Adv"},{"issue":"20","key":"3957_CR17","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","volume":"133","author":"P Karschnia","year":"2019","unstructured":"Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019;133(20):2212\u201321.","journal-title":"Blood"},{"issue":"14","key":"3957_CR18","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","volume":"5","author":"U Greenbaum","year":"2021","unstructured":"Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, et al. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv. 2021;5(14):2799\u2013806.","journal-title":"Blood Adv"},{"issue":"11","key":"3957_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005459","volume":"10","author":"Y Amidi","year":"2022","unstructured":"Amidi Y, Eckhardt CA, Quadri SA, Malik P, Firme MS, Jones DK, et al. Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy. J Immunother Cancer. 2022;10(11): e005459.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"3957_CR20","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jtct.2022.03.006","volume":"28","author":"SJ Grant","year":"2022","unstructured":"Grant SJ, Grimshaw AA, Silberstein J, Murdaugh D, Wildes TM, Rosko AE, et al. Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review. Transplant Cell Ther. 2022;28(6):294\u2013302.","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"3957_CR21","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1001\/jamaneurol.2020.2703","volume":"77","author":"DB Rubin","year":"2020","unstructured":"Rubin DB, Al Jarrah A, Li K, LaRose S, Monk AD, Ali AB, et al. Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy. JAMA Neurol. 2020;77(12):1536\u201342.","journal-title":"JAMA Neurol"},{"issue":"5","key":"3957_CR22","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1093\/brain\/awz053","volume":"142","author":"DB Rubin","year":"2019","unstructured":"Rubin DB, Danish HH, Ali AB, Li K, LaRose S, Monk AD, et al. Neurological toxicities associated with chimeric antigen receptor T-cell therapy. Brain. 2019;142(5):1334\u201348.","journal-title":"Brain"},{"issue":"23","key":"3957_CR23","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1182\/blood.2020008865","volume":"137","author":"P Strati","year":"2021","unstructured":"Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, et al. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood. 2021;137(23):3272\u20136.","journal-title":"Blood"},{"issue":"4","key":"3957_CR24","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"3957_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.2397-2335.1922.tb00768.x","volume":"85","author":"RA Fisher","year":"2018","unstructured":"Fisher RA. On the interpretation of \u03c72 from contingency tables, and the calculation of P. J R Stat Soc Ser A (Stat Soc). 2018;85(1):87\u201394.","journal-title":"J R Stat Soc Ser A (Stat Soc)"},{"issue":"1","key":"3957_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1214\/aoms\/1177730491","volume":"18","author":"HB Mann","year":"1947","unstructured":"Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat. 1947;18(1):50\u201360.","journal-title":"Ann Math Stat"},{"issue":"260","key":"3957_CR27","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/01621459.1952.10483441","volume":"47","author":"WH Kruskal","year":"1952","unstructured":"Kruskal WH, Wallis WA. Use of ranks in one-criterion variance analysis. J Am Stat Assoc. 1952;47(260):583\u2013621.","journal-title":"J Am Stat Assoc"},{"issue":"282","key":"3957_CR28","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J American Statistical Association. 1958;53(282):457\u201381.","journal-title":"J American Statistical Association"},{"key":"3957_CR29","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/978-1-4612-4380-9_37","volume-title":"Breakthroughs in statistics: methodology and distribution","author":"DR Cox","year":"1992","unstructured":"Cox DR. Regression models and life-tables. In: Breakthroughs in statistics: methodology and distribution. New York, NY: Springer; 1992. p. 527\u201341."},{"issue":"3","key":"3957_CR30","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"26","key":"3957_CR31","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"3","key":"3957_CR32","doi-asserted-by":"publisher","first-page":"187","DOI":"10.4274\/tjh.galenos.2023.2023.0136","volume":"40","author":"C Messerli","year":"2023","unstructured":"Messerli C, Wiedemann G, Porret N, Nagler M, Seipel K, Jeker B, et al. Correlation of peripheral chimeric antigen receptor T-cell (CAR-T cell) mRNA expression levels with toxicities and outcomes in patients with diffuse large B-cell lymphoma. Turk J Haematol. 2023;40(3):187\u201396.","journal-title":"Turk J Haematol"},{"issue":"12","key":"3957_CR33","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1182\/bloodadvances.2024012637","volume":"8","author":"MP Hamilton","year":"2024","unstructured":"Hamilton MP, Craig E, Gentille Sanchez C, Mina A, Tamaresis J, Kirmani N, et al. CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity. Blood Adv. 2024;8(12):3314\u201326.","journal-title":"Blood Adv"},{"issue":"11","key":"3957_CR34","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1182\/bloodadvances.2020003959","volume":"5","author":"FA Ayuk","year":"2021","unstructured":"Ayuk FA, Berger C, Badbaran A, Zabelina T, Sonntag T, Riecken K, et al. Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting. Blood Adv. 2021;5(11):2523\u20137.","journal-title":"Blood Adv"},{"issue":"21","key":"3957_CR35","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi L-A, Li D, Gust J, Liles WC, Wurfel MM, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy. Blood. 2017;130(21):2295\u2013306.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03957-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-03957-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-03957-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T11:17:36Z","timestamp":1750936656000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-03957-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3957"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-03957-7","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"31 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H. Kiyoi received research funding from FUJIFILM, Kyowa-Kirin, Bristol-Myers Squibb, Otsuka, Perseus Proteomics, Daiichi Sankyo, Abbvie, CURED, Astellas Pharma, Chugai, Zenyaku Kogyo, Nippon Shinyaku, Eisai, Takeda, Sumitomo Pharma, Sanofi, and Honoraria from Abbvie, Chugai, Astellas Pharma, and Novartis. K. Shimada reports grants from Otsuka and Kyowa Kirin, outside of the submitted work; consulting fees from Chugai, Eli Lilly, AbbVie, Kyowa Kirin, BeiGene, Ohara, Janssen, and Daiichi Sankyo, outside of the submitted work; payment or honoraria from Takeda, Kyowa Kirin, CSL Behring, Eisai, Chugai, Daiichi Sankyo, AstraZeneca, Janssen, Bristol-Myers Squibb, Nippon Shinyaku, Ono, Gilead, AbbVie, Genmab, Novartis, Incyte, Meiji Seika Pharma, Mundi Pharma, SymBio, Sanofi, Asahi Kasei, and Ohara, outside of the submitted work. The other authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}